NC Medial Research Inc
This is an initial Phase1/2 dose-finding, double-blind, placebo-controlled, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 24 hours of stroke onset. This study will be conducted in 2 stages.
|Study Type :||Interventional|
|Estimated Enrollment :||16 participants|
|Official Title:||A Phase 1/2, Dose-finding, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability of NCS-01 in Patients With Acute Ischemic Stroke|
|Actual Study Start Date :||February 27, 2020|
|Estimated Primary Completion Date :||October 2023|
|Estimated Study Completion Date :||October 2024|
human bone marrow derived cells
Placebo Comparator: Placebo
|Ages Eligible for Study:||18 Years to 80 Years|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
The University of Texas
Houston, Texas, United States, 77030